Welcome to Finance Insider, Business Insider’s summary of the top stories of the past 24 hours. Sign up here to get the best of Business Insider delivered direct to your inbox.
There’s a $US60 billion bidding war brewing for Shire, the maker of ADHD medications like Adderall.
Shire has already rejected an offer of that amount from Japan’s Takeda. Shire said in a statement that Takeda’s $US60 billion bid “continues to significantly undervalue the company and Shire’s growth prospects and pipeline.”
Allergan then confirmed it was “in the early stages of considering a possible offer” for Shire. That sent Allergan’s stock price plummeting, falling more than 8%. CNBC then reported Thursday afternoon that Allergan would not make a bid for Shire, with Allergan’s share price rebounding. What a wild ride.
Elsewhere in healthcare news, a leaked video shows Theranos employees playing the video game they created where you shoot at the reporter who exposed the startup’s problems.
In markets news:
- The stock market’s ‘secret medication for longevity’ has vanished – and that leaves it highly vulnerable to a meltdown
- Wall Street agrees that earnings season will send stocks soaring – here are 5 trades to help you make the most of it
- Tesla’s Model 3 struggles have traders paying record prices to protect against a stock drop
- Wall Street to Tesla: ‘What happened?’
- ‘Patience is wearing thin’: Wall Street is souring on IBM’s turnaround story
- One of the banks behind Dropbox’s IPO is already warning investors to be careful
- MoviePass’ parent company is getting crushed after selling shares at massive discount
Lastly, a trader named Morgan Stanley left Morgan Stanley and now someone is selling his business cards for $US1 million.
Business Insider Emails & Alerts
Site highlights each day to your inbox.